New: NCI-funded clinical trial search
Mednet Logo

How have the results of the SUNMO trial with mosunetuzumab/polatuzumab vedotin impacted your treatment choices for transplant ineligible relapsed/refractory DLBCL?

Community PollStarted

If mosun-pola is approved for transplant-ineligible, CAR-T-eligible R/R DLBCL in the 2L setting, how would you sequence it relative to CAR-T?

22 physicians have voted

Join Mednetto vote and see how they answered.

2 Answers
Mednet Member
Medical Oncology · IHA Hem Onc Consult
Answered on

Mosunetuzumab/polatuzumab is an effective salvage regimen for patients with R/R DLBCL (ORR 70%, CR 51%, and PFS 11.5 months) with a manageable toxicity profile. This, and other bispecific combinations, address the short PFS associated with single-agent bispecific antibody use. It is endorsed by the ...

Join for free or sign in to see the full answer

Mednet MemberInvited Expert
Medical Oncology · City of Hope
Answered on

The SUNMO trial results have provided another option for patients with relapsed and/or refractory disease who aren't fit enough for more intensive therapy, whether it be salvage + ASCT for relapsed or CAR-T/bispecific + CIT for those with refractory disease. As well, the regimen is likely to have le...

Join for free or sign in to see the full answer